WO2007042341A1 - Nutrition for obese patients - Google Patents

Nutrition for obese patients Download PDF

Info

Publication number
WO2007042341A1
WO2007042341A1 PCT/EP2006/065562 EP2006065562W WO2007042341A1 WO 2007042341 A1 WO2007042341 A1 WO 2007042341A1 EP 2006065562 W EP2006065562 W EP 2006065562W WO 2007042341 A1 WO2007042341 A1 WO 2007042341A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
vitamin
source
protein
total calories
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/065562
Other languages
French (fr)
Inventor
Claudia Roessle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2006301389A priority Critical patent/AU2006301389B9/en
Priority to MX2008002701A priority patent/MX2008002701A/en
Priority to CN2006800311644A priority patent/CN101247735B/en
Priority to BRPI0615396-8A priority patent/BRPI0615396A2/en
Priority to US12/064,686 priority patent/US20090220637A1/en
Priority to EP06841257A priority patent/EP1921928A1/en
Application filed by Nestec SA filed Critical Nestec SA
Priority to JP2008527464A priority patent/JP2009506012A/en
Priority to CA2620366A priority patent/CA2620366C/en
Publication of WO2007042341A1 publication Critical patent/WO2007042341A1/en
Priority to IL188847A priority patent/IL188847A0/en
Anticipated expiration legal-status Critical
Priority to US14/053,192 priority patent/US9549569B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • This invention relates generally to compositions and methods for the treatment and nutritional support of patients. More specifically, this invention relates to the nutritional support of obese patients prior to, during and after hospitalisation for surgery, treatment of diseases or other disorders as well as during periods of convalescence.
  • Obesity is classically defined based on the percentage of body fat or, more recently, the body mass index or BMI.
  • the BMI is defined as the ratio of weight in Kg divided by the height in metres, squared.
  • obese patients have pre-existing chronic diseases related to their obesity such as impaired glycaemic control, diabetes mellitus, coronary artery disease, hypertension, respiratory abnormalities, hyperlipidaemia, degenerative joint disease, and hepatobiliary disease that are likely to complicate even routine hospital care.
  • obese patients are more likely than their non-obese counterparts to develop postoperative complications such as impaired wound-healing, nosocomial infections, respiratory complications, and delayed cardiac recuperation.
  • obesity BMI greater than 30
  • Obesity entails increased oxidative stress and, in many cases, sarcopenia.
  • hypocaloric enteral nutritional support by which the authors meant feeding a composition with an energy density of at least 1.0 kcal/ml was at least as effective as eucaloric feeding in this group.
  • hypocaloric enteral nutritional support by which the authors meant feeding a composition with an energy density of at least 1.0 kcal/ml was at least as effective as eucaloric feeding in this group.
  • hypocaloric enteral nutritional support by which the authors meant feeding a composition with an energy density of at least 1.0 kcal/ml
  • this invention provides the use of a protein source, Vitamin A, Vitamin C, Vitamin E, zinc and selenium in the manufacture of a composition for the prevention or treatment of malnutrition in an obese patient wherein the composition has an energy density between 0.4 and 0.9 kcal/ml and comprises per litre at least 500 ⁇ g RE of Vitamin A, 70mg of Vitamin C, 9.0 mg ⁇ TE of Vitamin E, 4.0 mg zinc and 30 mg selenium and the protein source comprises at least 30% by weight whey protein and provides at least 30% of the total calories of the composition.
  • this invention provides a nutritional composition for the prevention or treatment of malnutrition in an obese patient which composition has an energy density between 0.4 and 0.9 kcal/ml and comprises per litre at least 500 ⁇ g RE of Vitamin A, 70 mg of Vitamin C, 9.0 mg ⁇ TE of Vitamin E, 4.0 mg zinc and 30 mg selenium and a protein source which provides at least 30% of the total calories of the composition wherein at least 30% by weight of the protein source is whey protein.
  • this invention provides the use of a protein source, a carbohydrate source, and a lipid source in the manufacture of a composition for the prevention or treatment of malnutrition in an obese patient wherein the composition has an energy density between 0.4 and 0.9 kcal/ml and the protein source comprises at least 30% by weight whey protein and provides at least 30% of the total calories of the composition.
  • this invention provides a nutritional composition for the prevention or treatment of malnutrition in an obese patient which composition has an energy density between 0.4 and 0.9 kcal/ml and comprises a protein source which provides at least 30% of the total calories of the composition, a carbohydrate source and a lipid source wherein at least 30% by weight of the protein source is whey protein.
  • this invention provides a method of preventing or treating malnutrition in an obese patient in need thereof by administering a therapeutic amount of a nutritional composition comprising a protein source wherein the composition has an energy density between 0.4 and 0.9 kcal/ml and the protein source comprises at least 30% by weight of whey protein and provides at least 30% of the total calories of the composition.
  • whey protein constitutes at least 50% of the protein source, more preferably from 60 to 85% of the protein source.
  • the protein source may provide 30 to 65% of the total calories of the composition, preferably from 35 to 50% and more preferably 40 to 50% of the total calories of the composition.
  • the composition may be a nutritional supplement, that is, nutritionally incomplete and intended to be consumed in addition to other foodstuffs or it may be nutritionally complete, including a carbohydrate source and a lipid source in addition to the protein source. It may be formulated as a ready to consume liquid for sip feeding or tube feeding, as a powdered composition which may be reconstituted with water prior to being fed orally or administered by tube feeding, as a semi-liquid food such as a spoonable dessert or in any other appropriate form e.g. bars, biscuits etc.
  • the carbohydrate source may provide 20 to 50% of the total calories of the composition and preferably from 25 to 45% of the total calories of the composition.
  • the lipid source may provide 10 to 40% of the total calories of the composition and preferably from 25 to 30% of the total calories of the composition.
  • obese patient means an individual who is obese i.e. with a BMI greater than 30 and who is undergoing or requires or is convalescing from therapy or surgery for a related or unrelated condition.
  • related conditions include conditions that are thought to be linked with overweight and obesity such as development of metabolic syndrome and Type II diabetes.
  • references to components of the composition being present in a specified number of grams per litre refer in the context of powdered compositions to the composition after re-constitution.
  • Whey protein comprises at least 30% of the protein source in the composition of the invention, preferably at least 50% and more preferably from 60 to 85% of the protein source.
  • Whey protein has fast gastric emptying and is associated with an increased satiety response so is suitable for a hypocaloric composition for obese patients. Further, it has been shown to stimulate insulin release in healthy subjects as well as those suffering from Type II diabetes and is thus a suitable protein source for individuals who may suffer from impaired glycaemic control. Whey protein has also been demonstrated to stimulate postprandial protein accretion; in particular in elderly subjects suggesting that protein losses can be limited by intake of whey protein. It is also a rich source of branched-chain amino acids which it is believed may be associated with the stimulation of protein synthesis.
  • whey protein is a rich source of cysteine which is a key constituent of glutathione, a major endogenous antioxidant. It has been shown that cysteine and glutathione are depleted in critically ill patients and that supplementation with cysteine can attenuate this depletion. Finally, whey protein is believed to have antiinflammatory properties which may be of relevance in the treatment of conditions such as obesity which are thought to engender chronic low-level inflammation.
  • the whey protein may be intact or partially or extensively hydrolysed. Mixtures of intact and hydrolysed whey proteins may be used.
  • the balance of the protein source may be any suitable protein such as defatted milk protein, soy protein or casein, in each case either in the intact form or hydrolysed. Mixtures of the above proteins may also be used as may mixtures of intact and hydrolysed proteins. Free amino acids such as Leucine may also be added.
  • the lipid source if present preferably does not contribute more than 40% of the total calories of the composition since the use of endogenous lipid stores should be stimulated in obese patients. Nevertheless, essential fatty acid intake should be considered.
  • n-6 polyunsaturated fats should preferably be avoided where there is a risk of stress and inflammatory conditions.
  • the ratio of n6/n3 fatty acids should be between 2: 1 and 6: 1.
  • These requirements can, for example, be met by using a blend of canola oil, corn oil and high-oleic acid sunflower oil supplemented with a source rich in n3 PUFA such as fish oil if a higher n3 content is required.
  • the lipid source may also include medium chain triglycerides if required.
  • the nutritional composition of the present invention may contain a carbohydrate source.
  • the carbohydrate source should be slowly digested or metabolised independently of insulin, thus avoiding high post-prandial glycaemic peaks.
  • Suitable carbohydrate sources are modified starches such as modified potato or tapioca starch, dextrins such as tapioca dextrin, isomaltulose, trehalose, tagatose, fructose and polyols such as xylitol and sorbitol as well as mixtures thereof.
  • the composition may also contain minerals, micronutrients and trace elements in accordance with the recommendations of Government bodies such as the USRDA.
  • the composition contains elevated amounts of Vitamins A, C, and E, zinc and selenium, for example, per litre at least:- 500 ⁇ g RE of Vitamin A, 70 mg of Vitamin C, 9.0 mg ⁇ TE of Vitamin E, 4.0 mg zinc and 30 mg selenium, more preferably per litre at least:- 1000 ⁇ g RE of Vitamin A, 125mg of Vitamin C, 15.0 mg ⁇ TE of Vitamin E, 10.0 mg zinc and 100 mg selenium.
  • the composition preferably also contains elevated amounts of iron, calcium, folate, Vitamin B 12, Vitamin D and Vitamin K, for example, per litre at least 6mg iron, 500mg calcium, 160mg folate, 2.0 ⁇ g Vitamin B 12, 8 ⁇ g Vitamin D and 60 ⁇ g Vitamin K.
  • the composition may further contain a source of dietary fibre.
  • Dietary fibre passes through the small intestine undigested by enzymes and functions as a natural bulking agent and laxative. Dietary fibre may be soluble or insoluble and in general a blend of the two types is preferred. Suitable sources of dietary fibre include soy, oat and gum Arabic and mixtures thereof.
  • a particularly preferred fibre blend is a mixture of outer pea fibre (predominantly insoluble), inner pea fibre, acacia gum and short chain fructo-oligosaccharides (all soluble).
  • the fibre content is between 10 and 40 g/1.
  • the composition may be manufactured in any suitable manner.
  • the composition may be manufactured by blending together the protein source, the carbohydrate source (if present), and the lipid source (if present) in appropriate proportions.
  • emulsifiers may be included in the blend at this stage.
  • the vitamins and minerals may be added at this point but are usually added later to avoid thermal degradation. Any lipophilic vitamins, emulsifiers and the like may be dissolved into the lipid source prior to blending.
  • Water preferably water which has been subjected to reverse osmosis, may then be mixed in to form a liquid mixture.
  • the liquid mixture may then be thermally treated to reduce bacterial loads.
  • the liquid mixture may be rapidly heated to a temperature in the range of about 8O 0 C to about HO 0 C for about 5 seconds to about 5 minutes. This may be carried out by steam injection or by heat exchanger; for example a plate heat exchanger.
  • the liquid mixture may then be cooled to about 6O 0 C to about 85 0 C; for example by flash cooling.
  • the liquid mixture may then be homogenised; for example in two stages at about 7 MPa to about 40 MPa in the first stage and about 2 MPa to about 14 MPa in the second stage.
  • the homogenised mixture may then be further cooled and any heat sensitive components; such as vitamins and minerals may be added.
  • the pH and solids content of the homogenised mixture is conveniently standardised at this point.
  • the homogenised mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
  • a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.
  • the powder should have a moisture content of less than about 5% by weight.
  • the homogenised mixture is filled into suitable containers; preferably aseptically.
  • the composition may also be retorted in the container. Suitable apparatus for carrying out filling of this nature is commercially available.
  • the composition may be in the form of a ready to feed product having a solids content of about 10 to about 14% by weight or may be in the form of a concentrate; usually of solids content of about 20 to about 26% by weight.
  • whey protein isolate may be dissolved in demineralised water. After complete dissolution of the protein, the carbohydrate is added to the protein solution. After complete dissolution of the carbohydrate, the pH is adjusted to 3.0 at ambient temperature. The resulting solution is heat sterilised (e.g. UHT), cooled and the pH is adjusted to 6.8 under aseptic conditions.
  • a dispersion of defatted milk protein concentrate and tri-calcium-citrate in demineralised water is prepared.
  • the fat mix is warmed to 70° C and mono- diglycerides are dissolved in the fat.
  • the fat mix is emulsified together with the protein dispersion using a colloidal mill.
  • the resulting coarse emulsion is homogenised at 200 bar/40 bar at ca 65° C.
  • the minerals, trace elements and vitamins are then added to the emulsion and its pH is adjusted to 6.8.
  • the resulting emulsion is UHT sterilised, flash-cooled to 70° C and then aseptically homogenised.
  • the emulsion is cooled to about 10° C and pumped to a sterile tank where it is mixed with the protein/carbohydrate phase After thorough mixing in the tank, the sterile composition is filled aseptically into the desired containers.
  • compositions include the following ingredients: protein: whey protein (50% by weight of total protein), defatted milk protein; carbohydrate: modified tapioca and corn starch; fat: about 50% canola oil, about 20% corn oil, about 30% high- oleic sunflower oil, n6:n3 ratio about 5; fibre (inner pea fibre, outer pea fibre and fructo-oligosaccharides); water; vitamin A; vitamin C vitamin D; vitamin E; vitamin K; vitamin B 1 ; Vitamin B 2 ; vitamin B 6 ; niacin; folic acid; pantothenic acid; vitamin B 12 ; biotin; calcium; magnesium; zinc; iron; copper; manganese; iodine; sodium; potassium; chloride; chromium; molybdenum; fluoride and selenium.
  • protein whey protein (50% by weight of total protein), defatted milk protein
  • carbohydrate modified tapioca and corn starch
  • fat about 50% canola oil, about 20% corn oil, about 30% high
  • compositions have the following nutrient profiles (per 200ml serving):
  • Vitamin A ( ⁇ g RE) 210 210 E
  • Vitamin B2 (mg) 0.36 0.36
  • Vitamin B 6 (mg) 0.42 0.42
  • Vitamin B 12 ( ⁇ g) 0.7 1.0 Biotin ( ⁇ g) 7.5 12
  • liquid tube feeding compositions according to the present invention are given below.
  • the compositions are given by way of illustration only.
  • compositions include the following ingredients: protein: hydrolysed whey protein (50% by weight of total protein), potassium caseinate; soy protein isolate; carbohydrate: modified tapioca and corn starch; fat: about 50% canola oil, about 20% corn oil, about 30% high-oleic sunflower oil, n6:n3 ratio about 5; fibre (inner pea fibre, outer pea fibre, acacia gum and fructo-oligosaccharides); water; vitamin A; vitamin C vitamin D; vitamin E; vitamin K; vitamin B 1 ; Vitamin B 2 ; vitamin B 6 ; niacin; folic acid; pantothenic acid; vitamin B 12 ; biotin; calcium; magnesium; zinc; iron; copper; manganese; iodine; sodium; potassium; chloride; chromium; molybdenum; fluoride and selenium.
  • protein hydrolysed whey protein (50% by weight of total protein), potassium caseinate
  • carbohydrate modified tapioca and corn starch
  • fat about 50% can
  • compositions have the following nutrient profiles (per 1500ml):
  • Vitamin D ( ⁇ g) 22.5 22.5
  • Vitamin E (mg ⁇ TE) 30 30
  • Vitamin B2 (mg) 3.0 3.0
  • Vitamin B 6 (mg) 3.9 3.9 Folic Acid ( ⁇ g) 540 54Og
  • Vitamin B 12 ( ⁇ g) 6.75 6.75

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Pediatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides a composition and method for providing nutritional support to obese patients. The composition has an energy density between 0.4 and 0.9 kcal/ml and comprises a protein source which comprises at least 30% by weight whey protein and provides at least 30% of the total calories of the composition. The composition may include a carbohydrate source and a lipid source. Preferably, at least 50% by weight of the protein source is whey protein. The invention further extends to use of the composition in the prevention or treatment of malnutrition in obese patients.

Description

Nutrition for Obese Patients
This invention relates generally to compositions and methods for the treatment and nutritional support of patients. More specifically, this invention relates to the nutritional support of obese patients prior to, during and after hospitalisation for surgery, treatment of diseases or other disorders as well as during periods of convalescence.
The prevalence of obesity in adults, children and adolescents has increased rapidly over the past 30 years in the United States and globally and continues to rise.
Obesity is classically defined based on the percentage of body fat or, more recently, the body mass index or BMI. The BMI is defined as the ratio of weight in Kg divided by the height in metres, squared. As obesity becomes more prevalent in all age groups, it is inevitable that the number of patients in hospitals who are also obese will increase.
Many obese patients have pre-existing chronic diseases related to their obesity such as impaired glycaemic control, diabetes mellitus, coronary artery disease, hypertension, respiratory abnormalities, hyperlipidaemia, degenerative joint disease, and hepatobiliary disease that are likely to complicate even routine hospital care. In addition, obese patients are more likely than their non-obese counterparts to develop postoperative complications such as impaired wound-healing, nosocomial infections, respiratory complications, and delayed cardiac recuperation. In adult intensive care patients, obesity (BMI greater than 30) has even been reported to be significantly associated with increased risk of mortality. Obesity entails increased oxidative stress and, in many cases, sarcopenia. It is well known that acute illness and/or surgical intervention is also associated with oxidative stress as well as negative nitrogen balance and loss of muscle mass, and in many cases insulin resistance is enhanced. In other words, acute illness is likely to exacerbate physiological and metabolic alterations already present at baseline in obese patients.
Recently, Dickerson et al (Nutrition 18:241 - 246 2002) compared the effects of hypocaloric and eucaloric enteral tube feeding in critically ill obese patients. Their results suggested that hypocaloric enteral nutritional support ( by which the authors meant feeding a composition with an energy density of at least 1.0 kcal/ml) was at least as effective as eucaloric feeding in this group. In the more generalised group of obese patients who, although ill, are not critically ill, there is a tendency for the nutrition offered post operatively in particular to be less than ideal. These patients tend to be offered either the same feeds as non-obese patients and thus ingest calories they do not require. Alternatively, it is assumed that in the short term no nutritional support at all is needed because the patients are calorically abundant. However, this overlooks the possibility that, when stressed for example by illness or surgery, obese patients may suffer from protein and micronutrient depletion just as non-obese patients do. Further, as noted above, obese patients are at greater risk of postoperative complications and would be in better conditions to resist these complications if they were not further weakened by impaired nutritional status. A need therefore exists for a nutritional composition designed to meet the nutritional needs of patients who are obese.
Summary of the Invention
In a first aspect, this invention provides the use of a protein source, Vitamin A, Vitamin C, Vitamin E, zinc and selenium in the manufacture of a composition for the prevention or treatment of malnutrition in an obese patient wherein the composition has an energy density between 0.4 and 0.9 kcal/ml and comprises per litre at least 500 μg RE of Vitamin A, 70mg of Vitamin C, 9.0 mg α TE of Vitamin E, 4.0 mg zinc and 30 mg selenium and the protein source comprises at least 30% by weight whey protein and provides at least 30% of the total calories of the composition.
In a second aspect, this invention provides a nutritional composition for the prevention or treatment of malnutrition in an obese patient which composition has an energy density between 0.4 and 0.9 kcal/ml and comprises per litre at least 500 μg RE of Vitamin A, 70 mg of Vitamin C, 9.0 mg α TE of Vitamin E, 4.0 mg zinc and 30 mg selenium and a protein source which provides at least 30% of the total calories of the composition wherein at least 30% by weight of the protein source is whey protein.
In a third aspect, this invention provides the use of a protein source, a carbohydrate source, and a lipid source in the manufacture of a composition for the prevention or treatment of malnutrition in an obese patient wherein the composition has an energy density between 0.4 and 0.9 kcal/ml and the protein source comprises at least 30% by weight whey protein and provides at least 30% of the total calories of the composition.
In a fourth aspect, this invention provides a nutritional composition for the prevention or treatment of malnutrition in an obese patient which composition has an energy density between 0.4 and 0.9 kcal/ml and comprises a protein source which provides at least 30% of the total calories of the composition, a carbohydrate source and a lipid source wherein at least 30% by weight of the protein source is whey protein.
In a fifth aspect, this invention provides a method of preventing or treating malnutrition in an obese patient in need thereof by administering a therapeutic amount of a nutritional composition comprising a protein source wherein the composition has an energy density between 0.4 and 0.9 kcal/ml and the protein source comprises at least 30% by weight of whey protein and provides at least 30% of the total calories of the composition.
Preferably whey protein constitutes at least 50% of the protein source, more preferably from 60 to 85% of the protein source.
In the event that the nutritional composition comprises a source of carbohydrates and a source of lipids, the protein source may provide 30 to 65% of the total calories of the composition, preferably from 35 to 50% and more preferably 40 to 50% of the total calories of the composition.
The composition may be a nutritional supplement, that is, nutritionally incomplete and intended to be consumed in addition to other foodstuffs or it may be nutritionally complete, including a carbohydrate source and a lipid source in addition to the protein source. It may be formulated as a ready to consume liquid for sip feeding or tube feeding, as a powdered composition which may be reconstituted with water prior to being fed orally or administered by tube feeding, as a semi-liquid food such as a spoonable dessert or in any other appropriate form e.g. bars, biscuits etc.
If present, the carbohydrate source may provide 20 to 50% of the total calories of the composition and preferably from 25 to 45% of the total calories of the composition.
If present, the lipid source may provide 10 to 40% of the total calories of the composition and preferably from 25 to 30% of the total calories of the composition.
Detailed description of the invention In this specification, the term "obese patient" means an individual who is obese i.e. with a BMI greater than 30 and who is undergoing or requires or is convalescing from therapy or surgery for a related or unrelated condition. Examples of "related conditions" include conditions that are thought to be linked with overweight and obesity such as development of metabolic syndrome and Type II diabetes.
References to components of the composition being present in a specified number of grams per litre refer in the context of powdered compositions to the composition after re-constitution.
Whey protein comprises at least 30% of the protein source in the composition of the invention, preferably at least 50% and more preferably from 60 to 85% of the protein source. Whey protein has fast gastric emptying and is associated with an increased satiety response so is suitable for a hypocaloric composition for obese patients. Further, it has been shown to stimulate insulin release in healthy subjects as well as those suffering from Type II diabetes and is thus a suitable protein source for individuals who may suffer from impaired glycaemic control. Whey protein has also been demonstrated to stimulate postprandial protein accretion; in particular in elderly subjects suggesting that protein losses can be limited by intake of whey protein. It is also a rich source of branched-chain amino acids which it is believed may be associated with the stimulation of protein synthesis. Further, whey protein is a rich source of cysteine which is a key constituent of glutathione, a major endogenous antioxidant. It has been shown that cysteine and glutathione are depleted in critically ill patients and that supplementation with cysteine can attenuate this depletion. Finally, whey protein is believed to have antiinflammatory properties which may be of relevance in the treatment of conditions such as obesity which are thought to engender chronic low-level inflammation. The whey protein may be intact or partially or extensively hydrolysed. Mixtures of intact and hydrolysed whey proteins may be used. The balance of the protein source may be any suitable protein such as defatted milk protein, soy protein or casein, in each case either in the intact form or hydrolysed. Mixtures of the above proteins may also be used as may mixtures of intact and hydrolysed proteins. Free amino acids such as Leucine may also be added..
The lipid source if present preferably does not contribute more than 40% of the total calories of the composition since the use of endogenous lipid stores should be stimulated in obese patients. Nevertheless, essential fatty acid intake should be considered.
A high intake of n-6 polyunsaturated fats should preferably be avoided where there is a risk of stress and inflammatory conditions. Preferably, the ratio of n6/n3 fatty acids should be between 2: 1 and 6: 1. These requirements can, for example, be met by using a blend of canola oil, corn oil and high-oleic acid sunflower oil supplemented with a source rich in n3 PUFA such as fish oil if a higher n3 content is required. The lipid source may also include medium chain triglycerides if required.
The nutritional composition of the present invention may contain a carbohydrate source. Preferably, the carbohydrate source should be slowly digested or metabolised independently of insulin, thus avoiding high post-prandial glycaemic peaks. Suitable carbohydrate sources are modified starches such as modified potato or tapioca starch, dextrins such as tapioca dextrin, isomaltulose, trehalose, tagatose, fructose and polyols such as xylitol and sorbitol as well as mixtures thereof.
The composition may also contain minerals, micronutrients and trace elements in accordance with the recommendations of Government bodies such as the USRDA. Preferably the composition contains elevated amounts of Vitamins A, C, and E, zinc and selenium, for example, per litre at least:- 500 μg RE of Vitamin A, 70 mg of Vitamin C, 9.0 mg α TE of Vitamin E, 4.0 mg zinc and 30 mg selenium, more preferably per litre at least:- 1000 μg RE of Vitamin A, 125mg of Vitamin C, 15.0 mg α TE of Vitamin E, 10.0 mg zinc and 100 mg selenium.
The composition preferably also contains elevated amounts of iron, calcium, folate, Vitamin B 12, Vitamin D and Vitamin K, for example, per litre at least 6mg iron, 500mg calcium, 160mg folate, 2.0 μg Vitamin B 12, 8 μg Vitamin D and 60 μg Vitamin K.
The composition may further contain a source of dietary fibre. Dietary fibre passes through the small intestine undigested by enzymes and functions as a natural bulking agent and laxative. Dietary fibre may be soluble or insoluble and in general a blend of the two types is preferred. Suitable sources of dietary fibre include soy, oat and gum Arabic and mixtures thereof. A particularly preferred fibre blend is a mixture of outer pea fibre (predominantly insoluble), inner pea fibre, acacia gum and short chain fructo-oligosaccharides (all soluble). Preferably, if fibre is present the fibre content is between 10 and 40 g/1.
The composition may be manufactured in any suitable manner. For example, the composition may be manufactured by blending together the protein source, the carbohydrate source (if present), and the lipid source (if present) in appropriate proportions. If used, emulsifiers may be included in the blend at this stage. The vitamins and minerals may be added at this point but are usually added later to avoid thermal degradation. Any lipophilic vitamins, emulsifiers and the like may be dissolved into the lipid source prior to blending. Water, preferably water which has been subjected to reverse osmosis, may then be mixed in to form a liquid mixture. The liquid mixture may then be thermally treated to reduce bacterial loads. For example, the liquid mixture may be rapidly heated to a temperature in the range of about 8O0C to about HO0C for about 5 seconds to about 5 minutes. This may be carried out by steam injection or by heat exchanger; for example a plate heat exchanger.
The liquid mixture may then be cooled to about 6O0C to about 850C; for example by flash cooling. The liquid mixture may then be homogenised; for example in two stages at about 7 MPa to about 40 MPa in the first stage and about 2 MPa to about 14 MPa in the second stage. The homogenised mixture may then be further cooled and any heat sensitive components; such as vitamins and minerals may be added. The pH and solids content of the homogenised mixture is conveniently standardised at this point.
If it is desired to produce a powdered composition, the homogenised mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder. The powder should have a moisture content of less than about 5% by weight.
If it is desired to produce a liquid composition, the homogenised mixture is filled into suitable containers; preferably aseptically. However, the composition may also be retorted in the container. Suitable apparatus for carrying out filling of this nature is commercially available. The composition may be in the form of a ready to feed product having a solids content of about 10 to about 14% by weight or may be in the form of a concentrate; usually of solids content of about 20 to about 26% by weight.
Alternatively, to prepare a liquid composition based on intact whey proteins, whey protein isolate may be dissolved in demineralised water. After complete dissolution of the protein, the carbohydrate is added to the protein solution. After complete dissolution of the carbohydrate, the pH is adjusted to 3.0 at ambient temperature. The resulting solution is heat sterilised (e.g. UHT), cooled and the pH is adjusted to 6.8 under aseptic conditions.
Meanwhile, a dispersion of defatted milk protein concentrate and tri-calcium-citrate in demineralised water is prepared. The fat mix is warmed to 70° C and mono- diglycerides are dissolved in the fat. The fat mix is emulsified together with the protein dispersion using a colloidal mill. The resulting coarse emulsion is homogenised at 200 bar/40 bar at ca 65° C. The minerals, trace elements and vitamins are then added to the emulsion and its pH is adjusted to 6.8. The resulting emulsion is UHT sterilised, flash-cooled to 70° C and then aseptically homogenised. The emulsion is cooled to about 10° C and pumped to a sterile tank where it is mixed with the protein/carbohydrate phase After thorough mixing in the tank, the sterile composition is filled aseptically into the desired containers.
Example 1
Two examples of complete nutritional compositions for sip feeding according to the present invention are given below. The compositions are given by way of illustration only.
The compositions include the following ingredients: protein: whey protein (50% by weight of total protein), defatted milk protein; carbohydrate: modified tapioca and corn starch; fat: about 50% canola oil, about 20% corn oil, about 30% high- oleic sunflower oil, n6:n3 ratio about 5; fibre (inner pea fibre, outer pea fibre and fructo-oligosaccharides); water; vitamin A; vitamin C vitamin D; vitamin E; vitamin K; vitamin B1; Vitamin B2; vitamin B6; niacin; folic acid; pantothenic acid; vitamin B12; biotin; calcium; magnesium; zinc; iron; copper; manganese; iodine; sodium; potassium; chloride; chromium; molybdenum; fluoride and selenium.
The compositions have the following nutrient profiles (per 200ml serving):
Nutrient Composition Example A Example B
Caloric Density 0.5 kcal/ml 0.75 kcal/ml
Protein (g) 12 15
Carbohydrate (g) 6.8 11.25
Fat (g) 2.8 5
Dietary Fibre (g) 5.2 5.2
Vitamin A (μg RE) 210 210 E
Vitamin D (μg) 2.6 2.6
Vitamin E (mg α TE) 3.2 4.5 E
Vitamin K (μg) 13.8 13.8
Vitamin C (mg) 26 26
Vitamin B 1 (mg) 0.3 0.3
Vitamin B2 (mg) 0.36 0.36
Niacin (mg) 3.0 3.0
Vitamin B 6 (mg) 0.42 0.42
Folic Acid (μg) 60 60
Pantothenic Acid (mg) 1.2 1.2
Vitamin B 12 (μg) 0.7 1.0 Biotin (μg) 7.5 12
Calcium (mg) 240 240
Magnesium (mg) 40 40
Zinc (mg) 2.4 2.4
Iron (mg) 2.0 2.0
Copper (mg) 0.24 0.24
Manganese (mg) 0.5 0.5
Iodine (μg) 20 20
Sodium (mg) 70 70
Potassium (mg) 260 260
Chloride (mg) 140 140
Chromium (μg) 12.4 12.4
Molybdenum (μg) 15 15
Selenium (μg) 12.6 12.6
Fluoride (mg) 0.2 0.2
Example 2
Two examples of liquid tube feeding compositions according to the present invention are given below. The compositions are given by way of illustration only.
The compositions include the following ingredients: protein: hydrolysed whey protein (50% by weight of total protein), potassium caseinate; soy protein isolate; carbohydrate: modified tapioca and corn starch; fat: about 50% canola oil, about 20% corn oil, about 30% high-oleic sunflower oil, n6:n3 ratio about 5; fibre (inner pea fibre, outer pea fibre, acacia gum and fructo-oligosaccharides); water; vitamin A; vitamin C vitamin D; vitamin E; vitamin K; vitamin B1; Vitamin B2; vitamin B6; niacin; folic acid; pantothenic acid; vitamin B12; biotin; calcium; magnesium; zinc; iron; copper; manganese; iodine; sodium; potassium; chloride; chromium; molybdenum; fluoride and selenium.
The compositions have the following nutrient profiles (per 1500ml):
Nutrient Composition Example C Example D
Caloric Density 0.5 kcal/ml 0.75 kcal/ml
Protein (g) 84 100
Carbohydrate (g) 47 124
Fat (g) 25 37.5
Dietary Fibre (g) 22.5 22.5
Vitamin A (μg RE) 1950 1950
Vitamin D (μg) 22.5 22.5
Vitamin E (mg α TE) 30 30
Vitamin K (μg) 124.5 124.5
Vitamin C (mg) 225 225
Vitamin B 1 (mg) 2.7 2.7
Vitamin B2 (mg) 3.0 3.0
Niacin (mg) 27 27
Vitamin B 6 (mg) 3.9 3.9 Folic Acid (μg) 540 54Og
Pantothenic Acid (mg) 11.25 11.25
Vitamin B 12 (μg) 6.75 6.75
Biotin (μg) 67.5 67.5
Calcium (mg) 1350 1350
Magnesium (mg) 450 450
Zinc (mg) 22.5 22.5
Iron (mg) 24 24
Copper (mg) 2.25 2.25
Manganese (mg) 4.95 4.95
Iodine (μg) 225 225
Sodium (mg) 1350 1350
Potassium (mg) 2550 2550
Chloride (mg) 2100 2100
Chromium (μg) 112.5 112.5
Molybdenum (μg) 225 225
Selenium (μg) 112.5 112.5
Fluoride (mg) 2.25 2.25

Claims

Claims
1. Use of a protein source, Vitamin A, Vitamin C, Vitamin E, zinc and selenium in the manufacture of a composition for the prevention or
5 treatment of malnutrition in an obese patient wherein the composition has an energy density between 0.4 and 0.9 kcal/ml and comprises per litre at least 500 μg RE of Vitamin A, 70mg of Vitamin C, 9.0 mg α TE of Vitamin E, 4.0 mg zinc and 30 mg selenium and the protein source comprises at least 30% by weight whey protein and provides at least 30% of the total calories i o of the composition.
2. Use of a protein source, a carbohydrate source and a lipid source in the manufacture of a composition for the prevention or treatment of malnutrition in an obese patient wherein the composition has an energy density between
15 0.4 and 0.9 kcal/ml and the protein source provides comprises at least 30% by weight whey protein and at least 30% of the total calories of the composition.
3. The use of claim 1 or 2 wherein the composition comprises per litre at least 20 1000 μg RE of Vitamin A, 125mg of Vitamin C, 15.0 mg α TE of Vitamin
E, 10.0 mg zinc and 100 mg selenium.
4. The use of any preceding claim wherein at least 50% by weight of the protein source is whey protein.
25
5. The use of any preceding claim, wherein whey protein constitutes between 60 and 85% by weight of the protein source.
6. The use of any preceding claim, wherein the protein source provides from 40 to 50% of the total calories of the composition.
7. The use of any preceding claim, wherein the composition further comprises from 10 to 40 g/1 of dietary fibre.
8. The use of any of claims 2 to 7, wherein the carbohydrate source provides from 25 to 45% of the total calories of the composition.
9. The use of any of claims 2 to 8, wherein the lipid source provides from 25 to 30% of the total calories of the composition.
10. The use of any of claims 2 to 9, wherein the ratio of n6:n3 long chain polyunsaturated fatty acids in the lipid source is between 6: 1 and 2: 1.
11. A nutritional composition for the prevention or treatment of malnutrition in an obese patient which composition has an energy density between 0.4 and 0.9 kcal/ml and comprises at least 500 μg RE of Vitamin A, 70mg of Vitamin C, 9.0 mg α TE of Vitamin E, 4.0 mg zinc and 30 mg selenium and a protein source which provides at least 30% of the total calories of the composition, wherein at least 30% by weight of the protein source is whey protein.
12. A nutritional composition for the prevention or treatment of malnutrition in an obese patient which composition has an energy density between 0.4 and 0.9 kcal/ml and comprises a protein source which provides at least 30% of the total calories of the composition, a carbohydrate source and a lipid source wherein at least 30% by weight of the protein source is whey protein.
13. The composition of claim 11 or 12 wherein at least 50% by weight of the protein source is whey protein.
14. The composition of any of claims 11 to 13, wherein whey protein constitutes between 60 and 85% by weight of the protein source.
15. The composition of any of claims 11 to 14, wherein the protein source provides from 40 to 50% of the total calories of the composition.
16. The composition of any of claims 11 to 15 wherein the composition further comprises from 10 to 40 g/1 of dietary fibre
17. The composition of any of claims 12 to 16, wherein the carbohydrate source provides from 25 to 45% of the total calories of the composition.
18. The composition of any of claims 12 to 17, wherein the lipid source provides from 25 to 30% of the total calories of the composition.
19. The composition of any of claims 12 to 18, wherein the ratio of n6:n3 long chain polyunsaturated fatty acids in the lipid source is between 6: 1 and 2: 1.
20. The composition of any of claims 11 to 19, wherein the composition further comprises per litre at least 1000 μg RE of Vitamin A, at least 125mg of Vitamin C, at least 15.0 mg α TE of Vitamin E, at least 10.0 mg zinc and at least 100 mg selenium.
PCT/EP2006/065562 2005-08-26 2006-08-22 Nutrition for obese patients Ceased WO2007042341A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2008527464A JP2009506012A (en) 2005-08-26 2006-08-22 Nutrients in obese patients
MX2008002701A MX2008002701A (en) 2005-08-26 2006-08-22 Nutrition for obese patients.
CN2006800311644A CN101247735B (en) 2005-08-26 2006-08-22 nutrition for obese patients
BRPI0615396-8A BRPI0615396A2 (en) 2005-08-26 2006-08-22 nutritional composition for the prevention or treatment of malnutrition in an obese patient, as well as the use of a source of protein, vitamin a, vitamin c, vitamin e, zinc and selenium for its preparation
US12/064,686 US20090220637A1 (en) 2005-08-26 2006-08-22 Nutrition for obese patients
AU2006301389A AU2006301389B9 (en) 2005-08-26 2006-08-22 Nutrition for obese patients
CA2620366A CA2620366C (en) 2005-08-26 2006-08-22 Nutrition for obese patients
EP06841257A EP1921928A1 (en) 2005-08-26 2006-08-22 Nutrition for obese patients
IL188847A IL188847A0 (en) 2005-08-26 2008-01-17 Nutrition for obese patients
US14/053,192 US9549569B2 (en) 2005-08-26 2013-10-14 Nutrition for obese patients

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05018626.1 2005-08-26
EP05018626 2005-08-26
EP05110556.7 2005-11-09
EP05110556 2005-11-09

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/064,686 A-371-Of-International US20090220637A1 (en) 2005-08-26 2006-08-22 Nutrition for obese patients
US14/053,192 Continuation US9549569B2 (en) 2005-08-26 2013-10-14 Nutrition for obese patients

Publications (1)

Publication Number Publication Date
WO2007042341A1 true WO2007042341A1 (en) 2007-04-19

Family

ID=37735137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/065562 Ceased WO2007042341A1 (en) 2005-08-26 2006-08-22 Nutrition for obese patients

Country Status (13)

Country Link
US (2) US20090220637A1 (en)
EP (1) EP1921928A1 (en)
JP (2) JP2009506012A (en)
CN (1) CN101247735B (en)
AU (1) AU2006301389B9 (en)
BR (1) BRPI0615396A2 (en)
CA (1) CA2620366C (en)
IL (1) IL188847A0 (en)
MX (1) MX2008002701A (en)
MY (1) MY145662A (en)
RU (1) RU2385647C2 (en)
TW (1) TW200740379A (en)
WO (1) WO2007042341A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2221059A4 (en) * 2007-10-25 2010-12-15 Nutri Co Ltd COMPOSITION FOR REDUCING THE RATE OF GLUCOSE, LOW-DENSITY LIPOPROTEIN MODIFIED BY MALONDIALDEHYDE, HOMOCYSTEINE AND / OR C REACTIVE BLOOD PROTEIN
GB2504390A (en) * 2012-06-08 2014-01-29 Whey Forward Health Ind Ltd Composition comprising selenium, vitamin C and whey protein
CN102131405B (en) * 2008-06-19 2014-06-11 纽迪希亚公司 Liquid nutritional composition for bariatric surgery patients

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
ES2548432T3 (en) * 2005-12-19 2015-10-16 Abbott Laboratories Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in the production of type 1 and type 2 cytokines
BR112012018174A2 (en) 2010-01-29 2019-08-27 Abbott Lab aseptically packaged nutritional liquids comprising hmb.
JP5892948B2 (en) 2010-01-29 2016-03-23 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ Nutritional emulsion containing calcium HMB
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
TWI526161B (en) * 2010-06-10 2016-03-21 亞培公司 a substantially transparent nutrient solution comprising calcium HMB and soluble protein
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
IT1401720B1 (en) * 2010-07-20 2013-08-02 Picarelli DIETETIC AID FOR THE TREATMENT OF OBESITY AND OTHER PATHOLOGICAL CONDITIONS SUCH AS THE INSULIN RESISTANCE AND DIABETES MELLITUS TYPE 2
EP2670262B2 (en) 2011-02-02 2025-10-15 Société des Produits Nestlé S.A. High protein nutritional compositions and using same
AU2013392167B2 (en) * 2013-06-10 2017-04-27 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program
CN105992520A (en) * 2013-12-19 2016-10-05 雅培公司 Nutritional composition comprising hydrolyzed protein
CA3001091A1 (en) * 2015-11-20 2017-05-26 Nestec S.A. Methods using whey protein to improve or maintain muscle quality
ES3021188T3 (en) * 2015-11-30 2025-05-26 Fresenius Kabi Deutschland Gmbh High protein enteral tube feed for icu patients
CN105901701A (en) * 2016-04-18 2016-08-31 邱小文 Metabolic surgery nutritional agent
CN106880042A (en) * 2017-01-18 2017-06-23 恩施硒域传奇健康管理有限公司 A kind of full nutrition formula food suitable for fat, fat reducing patient with operation convalescence
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof
CN113331305A (en) * 2021-05-10 2021-09-03 江苏雅博动物健康科技有限责任公司 Meal replacement powder containing dietary fibers for pets

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968896A (en) * 1998-01-16 1999-10-19 Beth Israel Deaconess Medical Center Nutritional supplement for preoperative feeding
EP1302111A1 (en) * 2001-10-09 2003-04-16 Bariatrix Products International, Inc. Dietary composition and method
US20040258826A1 (en) * 2001-12-20 2004-12-23 Navarro Y Koren Peter Antonio Matrix-forming composition containing pectin
US20050233045A1 (en) * 2003-09-03 2005-10-20 Aldred Deborah L Satiety enhancing food compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3487079B2 (en) * 1996-06-17 2004-01-13 不二製油株式会社 Anti-obesity food
EP0891719A1 (en) * 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
AU9433698A (en) * 1998-10-09 2000-05-01 Sanacare Aps Diet food
GB9916536D0 (en) * 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
JP2001120227A (en) * 1999-10-29 2001-05-08 We'll Corporation:Kk Diet food
US20060159724A1 (en) * 2000-08-08 2006-07-20 Bell Stacey J Nutritional supplement for the management of weight
DE10057290B4 (en) * 2000-11-17 2004-01-08 Fresenius Kabi Deutschland Gmbh Enteral supplement for parenteral nutrition or partial enteral / oral nutrition for critically ill, chronically ill and malnourished
MY135783A (en) * 2001-09-07 2008-06-30 Meiji Dairies Corp Nutritional composition for controlling blood sugar level
MXPA05012702A (en) * 2003-05-28 2006-02-08 Unilever Nv Satiety enhancing food products.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968896A (en) * 1998-01-16 1999-10-19 Beth Israel Deaconess Medical Center Nutritional supplement for preoperative feeding
EP1302111A1 (en) * 2001-10-09 2003-04-16 Bariatrix Products International, Inc. Dietary composition and method
US20040258826A1 (en) * 2001-12-20 2004-12-23 Navarro Y Koren Peter Antonio Matrix-forming composition containing pectin
US20050233045A1 (en) * 2003-09-03 2005-10-20 Aldred Deborah L Satiety enhancing food compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1921928A1 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2221059A4 (en) * 2007-10-25 2010-12-15 Nutri Co Ltd COMPOSITION FOR REDUCING THE RATE OF GLUCOSE, LOW-DENSITY LIPOPROTEIN MODIFIED BY MALONDIALDEHYDE, HOMOCYSTEINE AND / OR C REACTIVE BLOOD PROTEIN
US10383893B2 (en) 2007-10-25 2019-08-20 Nutri Co., Ltd. Composition for reducing the level of glucose, malondialdehyde-modified LDL, homocysteine and/or C-reactive protein in blood
CN102131405B (en) * 2008-06-19 2014-06-11 纽迪希亚公司 Liquid nutritional composition for bariatric surgery patients
GB2504390A (en) * 2012-06-08 2014-01-29 Whey Forward Health Ind Ltd Composition comprising selenium, vitamin C and whey protein
GB2504390B (en) * 2012-06-08 2015-06-03 Whey Forward Health Ind Ltd Nutraceutical and pharmaceutical composition

Also Published As

Publication number Publication date
CA2620366C (en) 2014-04-01
CN101247735B (en) 2012-02-01
US20090220637A1 (en) 2009-09-03
AU2006301389A1 (en) 2007-04-19
IL188847A0 (en) 2008-04-13
AU2006301389B2 (en) 2011-04-28
RU2385647C2 (en) 2010-04-10
JP2009506012A (en) 2009-02-12
RU2008107342A (en) 2009-09-10
BRPI0615396A2 (en) 2011-05-17
MY145662A (en) 2012-03-15
MX2008002701A (en) 2008-03-18
US20140051627A1 (en) 2014-02-20
US9549569B2 (en) 2017-01-24
AU2006301389B9 (en) 2011-05-12
CN101247735A (en) 2008-08-20
EP1921928A1 (en) 2008-05-21
TW200740379A (en) 2007-11-01
CA2620366A1 (en) 2007-04-19
JP2013199471A (en) 2013-10-03

Similar Documents

Publication Publication Date Title
US9549569B2 (en) Nutrition for obese patients
CN102131405B (en) Liquid nutritional composition for bariatric surgery patients
EP1313376B1 (en) Nutritional composition
CA2234398C (en) Composition and method for providing nutrition to diabetics
US20090075862A1 (en) Method for providing glutamine
BRPI0914793B1 (en) nutritional composition and use of a nutritional composition
JP2003530411A (en) Composition containing free amino acid
BR112019009757B1 (en) PUFA, VITAMIN E, VITAMIN D AND THE AMINO ACIDS BOUND TO THE PROTEINS GLYCINE, ARGININE AND TRYPTOPHAN, THEIR USE IN THE MANUFACTURE OF A NUTRITIONAL COMPOSITION TO TREAT SARCOPENIA AND/OR WEAKNESS AND NUTRITIONAL COMPOSITION
TW202317083A (en) Enteral nutrient preparation
CN105992520A (en) Nutritional composition comprising hydrolyzed protein
WO1998054985A1 (en) Product and method for providing glutamine
MXPA98005035A (en) Composition and method for providing nutrition to diabeti
EP2299850A2 (en) Liquid nutritional composition for bariatric surgery patients
HK1039729B (en) Method for providing glutamine

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006841257

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 188847

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12008500133

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2006301389

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008527464

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 565925

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2006301389

Country of ref document: AU

Date of ref document: 20060822

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006301389

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2620366

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/002701

Country of ref document: MX

Ref document number: 2008107342

Country of ref document: RU

Ref document number: 200680031164.4

Country of ref document: CN

Ref document number: 1691/DELNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 08029344

Country of ref document: CO

WWP Wipo information: published in national office

Ref document number: 2006841257

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12064686

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0615396

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080227